CTMXCytomX Therapeutics, Inc.

$822M

Q4 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$27M+331.6% YoY

Gross Profit

$27M100.0% margin

Operating Income

-$1M-4.6% margin

Net Income

$621,0002.3% margin

EPS (Diluted)

$0.02

QoQ Revenue Growth

+12.1%

Cash Flow

Operating Cash Flow

$22M

Free Cash Flow

$22M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$398M

Total Liabilities

$328M

Stockholders' Equity

$70M

Cash & Equivalents

$178M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$27M	$6M	+331.6%
Gross Profit	$27M	$6M	+331.6%
Operating Income	-$1M	-$14M	+91.2%
Net Income	$621,000	-$14M	+104.4%

CTMX Q4 2017 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena